Company Profile
Company Overview
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), headquartered in Rockville, Maryland, is a biopharmaceutical company working to advance the science of personalized medicine to improve the lives of patients with central nervous system conditions, including schizophrenia. The company possesses a unique combination of experience with medical practice, drug development, and genetics and genomics. Mihael Polymeropoulos, M.D., President and Chief Executive Officer (CEO), co-founded Vanda, in partnership with the venture capital firm Care Capital LLC, and Bio*One Capital, an investment arm of the Singapore government.
Vanda uses novel technologies, including genetics and genomics, to inform the clinical development and commercial application of its compounds. Specifically, Vanda is focusing efforts on improving the understanding of genetic variability in individuals with schizophrenia to enable more informed decisions about drug therapy.
Benefits
Vanda offers competitive compensation and a comprehensive benefits package. Vanda is located minutes from Washington, DC, and will pay for relocation.